A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody

Immunology and Cell Biology

Volumn 88, Issue 5, 2010, Pages 605-611

  Pejoski, David ^a   Zeng, Weiguang ^a   Rockman, Steven ^b   Brown, Lorena E ^a   Jackson, David C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CSL LIMITED   (Australia)

Author keywords

influenza M2 ectodomain; influenza M2 protein; lipopeptide based vaccines

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; PROTEIN M2; INFLUENZA VACCINE; LIPOPEPTIDE; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS HEMAGGLUTININ;

AIRWAY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS A; MOUSE; NONHUMAN; VIRUS LOAD; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; NUCLEOTIDE SEQUENCE; ORTHOMYXOVIRIDAE INFECTIONS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONSERVED SEQUENCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTININS, VIRAL; INFLUENZA A VIRUS; INFLUENZA VACCINES; LIPOPEPTIDES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VIRAL MATRIX PROTEINS;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 77954315784     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.15     Document Type: Article

References (45)

1. Sugrue RJ, Hay AJ. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 1991; 180: 617-624.
2. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992; 69: 517-528.
3. Lamb RA, Choppin PW. Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. Virology 1981; 112: 729-737.
4. Park EK, Castrucci MR, Portner A, Kawaoka Y. The M2 ectodomain is important for its incorporation into influenza A virions. J Virol 1998; 72: 2449-2455.
5. Wang R, Song A, Levin J, Dennis D, Zhang NJ, Yoshida H et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 2008; 80: 168-177.
6. Gerhard W, Mozdzanowska K, Furchner M, Washko G, Maiese K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev 1997; 159: 95-103.
7. Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, Cramer DV et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006; 24: 5158-5168.
8. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004; 22: 2993-3003.
9. Liu W, Zou P, Chen YH. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 2004; 93: 131-136.
10. Mozdzanowska K, Zharikova D, Cudic M, Otvos L, Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 2007; 4: 118.
11. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007; 13: 426-435.
12. Zharikova D, Mozdzanowska K, Feng J, Zhang M, Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 2005; 79: 6644-6654.
13. Zou P, Liu W, Chen YH. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. Int Immunopharma-col 2005; 5: 631-635.
14. Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988; 62: 2762-2772.
15. Jackson DC, Tang XL, Murti KG, Webster RG, Tregear GW, Bean WJ. Electron microscopic evidence for the association of M2 protein with the influenza virion. Arch Virol 1991; 118: 199-207.
16. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004; 172: 5598-5605.
17. Wu F, Huang JH, Yuan XY, Huang WS, Chen YH. Characterization of immunity induced by M2e of influenza virus. Vaccine 2007; 25: 8868-8873.
18. Fiers W, De Filette M, Birkett A, Neirynck S, Minjou W. A 'universal' human influenza A vaccine. Virus Res 2004; 103: 173-176.
19. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos Jr L et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003; 21: 2616-2626.
20. Liu W, Li H, Chen YH. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol 2003; 35: 141-146.
21. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005; 337: 149-161.
22. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5: 1157-1163.
23. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 2008; 105: 5850-5855.
24. Batzloff MR, Hartas J, Zeng W, Jackson DC, Good MF. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J Infect Dis 2006; 194: 325-330.
25. Day EB, Zeng W, Doherty PC, Jackson DC, Kedzierska K, Turner SJ. The context of epitope presentation can influence functional quality of recalled influenza A virus-specific memory CD8+ T cells. J Immunol 2007; 179: 2187-2194.
26. Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, Cheers C et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 2004; 101: 15440-15445.
27. Zeng W, Gauci S, Ghosh S, Walker J, Jackson DC. Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH. Vaccine 2005; 23: 4427-4435.
28. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 2002; 169: 4905-4912.
29. Zeng W, Pagnon J, Jackson DC. The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function. Mol Immunol 2007; 44: 3724-3731.
30. Jackson DC, Purcell AW, Fitzmaurice CJ, Zeng W, Hart DN. The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer. Curr Drug Targets 2002; 3: 175-196.
31. Lau YF, Deliyannis G, Zeng W, Mansell A, Jackson DC, Brown LE. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int Immunol 2006; 18: 1801-1813.
32. Brown LE, Jackson DC. Lipid-based self-adjuvanting vaccines. Curr Drug Deliv 2005; 2: 383-393.
33. Jackson DC, Drummer HE, Brown LE. Conserved determinants for CD4+ T cells within the light chain of the H3 hemagglutinin molecule of influenza virus. Virology 1994; 198: 613-623.
34. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009; 8: 499-508.
35. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A et al. Potent immuno-genicity and efficacy of a universal influenza vaccine candidate comprising a recombi-nant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008; 26: 201-214.
36. Yu M, Zeng W, Pagnon J, Walker J, Ghosh S, Wang LF et al. Identification of dominant epitopes of synthetic immunocontraceptive vaccines that induce antibodies in dogs. Vaccine 2005; 23: 4589-4597.
37. Walker J, Ghosh S, Pagnon J, Colantoni C, Newbold A, Zeng W et al. Totallysynthetic peptide-based immunocontraceptive vaccines show activity in dogs of different breeds. Vaccine 2007; 25: 7111-7119.
38. Zeng W, Ghosh S, Macris M, Pagnon J, Jackson DC. Assembly of synthetic peptide vaccines by chemoselective ligation of epitopes: influence of different chemical linkages and epitope orientations on biological activity. Vaccine 2001; 19: 3843-3852.
39. Deliyannis G, Jackson DC, Ede NJ, Zeng W, Hourdakis I, Sakabetis E et al. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol 2002; 76: 4212-4221.
40. Ghosh S, Jackson DC. Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines. Int Immunol 1999; 11: 1103-1110.
41. Deliyannis G, Kedzierska K, Lau YF, Zeng W, Turner SJ, Jackson DC et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol 2006; 36: 770-778.
42. Kitikoon P, Strait EL, Thacker EL. The antibody responses to swine influenza virus (SIV) recombinant matrix 1 (rM1), matrix 2 (M2), and hemagglutinin (HA) proteins in pigs with different SIV exposure. Vet Microbiol 2008; 126: 51-62.
43. Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cyto-toxic T lymphocytes. Eur J Immunol 1993; 23: 1215-1219.
44. Jackson DC, Deliyannis G, Eriksson EM, Dinatale I, Rizkalla M, Gowans EJ. Dendritic cell immunotherapy of hepatitis C virus infection: toxicology of lipopeptide-loaded dendritic cells. Inter J Peptide Res Ther 2005; 11: 223-235.
45. Saelens X. The influenza matrix protein 2 as a vaccine target. Fut Virol 2008; 3: 167-178.